{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:53:29Z","timestamp":1791359609646,"version":"4.3.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008126","name":"Jeju National University Hospital","doi-asserted-by":"publisher","award":["2024-12"],"award-info":[{"award-number":["2024-12"]}],"id":[{"id":"10.13039\/501100008126","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.parkreldis.2026.108939","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:08:32Z","timestamp":1786979312000},"page":"108939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association of early adjunctive dopaminergic therapy and 5-year mortality in Parkinson's disease: A nationwide cohort study"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6710-9383","authenticated-orcid":false,"given":"Seung Hyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang Hyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngjoo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Su","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kye Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunghun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hwan","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4017-2056","authenticated-orcid":false,"given":"Ji-Hoon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9996","key":"10.1016\/j.parkreldis.2026.108939_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.parkreldis.2026.108939_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.parkreldis.2026.108939_bib3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1474-4422(20)30036-3","article-title":"Initiation of pharmacological therapy in Parkinson's disease: when, why, and how","volume":"19","author":"de Bie","year":"2020","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2026.108939_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamaneurol.2021.4736","article-title":"Long-term effectiveness of adjuvant treatment with Catechol-O-Methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists among patients with parkinson disease uncontrolled by levodopa therapy: the PD MED randomized clinical trial","volume":"79","author":"Gray","year":"2022","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.parkreldis.2026.108939_bib5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.parkreldis.2026.108939_bib6","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1001\/jamaneurol.2021.3926","article-title":"Association of physical activity, including amount and maintenance, with all-cause mortality in parkinson disease","volume":"78","author":"Yoon","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.parkreldis.2026.108939_bib7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.parkreldis.2020.10.017","article-title":"Effects of socioeconomic status on mortality after Parkinson's disease: a nationwide population-based matched cohort study in Korean populations","volume":"80","author":"Yoon","year":"2020","journal-title":"Park. Relat. Disord."},{"issue":"15","key":"10.1016\/j.parkreldis.2026.108939_bib8","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2026.108939_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jrsssb\/qkac001","article-title":"Estimating heterogeneous treatment effects with right-censored data via causal survival forests","volume":"85","author":"Cui","year":"2023","journal-title":"J. Roy. Stat. Soc. B Stat. Methodol."},{"key":"10.1016\/j.parkreldis.2026.108939_bib10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1214\/08-AOAS169","article-title":"Random survival forests","volume":"2","author":"Ishwaran","year":"2008","journal-title":"Ann. Appl. Stat."},{"key":"10.1016\/j.parkreldis.2026.108939_bib11","first-page":"1","article-title":"Qini curves for multi-armed treatment rules","author":"Sverdrup","year":"2024","journal-title":"J. Comput. Graph Stat."},{"issue":"4","key":"10.1016\/j.parkreldis.2026.108939_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1056\/NEJMoa1809983","article-title":"Randomized delayed-start trial of levodopa in Parkinson's Disease","volume":"380","author":"Verschuur","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.parkreldis.2026.108939_bib13","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/mds.29796","article-title":"Long-term Follow-Up of the LEAP study: early versus delayed levodopa in early Parkinson's Disease","volume":"39","author":"Frequin","year":"2024","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2026.108939_bib14","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/mds.25364","article-title":"Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease","volume":"28","author":"Warren Olanow","year":"2013","journal-title":"Mov. Disord."},{"issue":"Pt 10","key":"10.1016\/j.parkreldis.2026.108939_bib15","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/brain\/awu195","article-title":"The modern pre-levodopa era of Parkinson's disease: insights into motor complications from Sub-Saharan Africa","volume":"137","author":"Cilia","year":"2014","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.parkreldis.2026.108939_bib16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/14737175.2026.2645845","article-title":"Advances in the pharmacological management of early motor manifestations of Parkinson's disease (PD)","volume":"26","author":"M\u00fcller","year":"2026","journal-title":"Expert Rev. Neurother."},{"issue":"10","key":"10.1016\/j.parkreldis.2026.108939_bib17","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/mdc3.14174","article-title":"Effect of early levodopa treatment on mortality in people with Parkinson's Disease","volume":"11","author":"Talebi","year":"2024","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"4","key":"10.1016\/j.parkreldis.2026.108939_bib18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/WNF.0b013e31825f77b9","article-title":"Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial","volume":"35","author":"Mizuno","year":"2012","journal-title":"Clin. Neuropharmacol."},{"issue":"8","key":"10.1016\/j.parkreldis.2026.108939_bib19","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/mds.25877","article-title":"Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease","volume":"29","author":"Hauser","year":"2014","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.parkreldis.2026.108939_bib20","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/archneur.1989.00520460028009","article-title":"DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group","volume":"46","year":"1989","journal-title":"Arch. Neurol."},{"issue":"13","key":"10.1016\/j.parkreldis.2026.108939_bib21","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson's disease","volume":"361","author":"Olanow","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.parkreldis.2026.108939_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1468-1331.1999.tb00007.x","article-title":"SELEDO: a 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa","volume":"6","author":"Przuntek","year":"1999","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.parkreldis.2026.108939_bib23","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1177\/0091270005277935","article-title":"Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease","volume":"45","author":"Chen","year":"2005","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.parkreldis.2026.108939_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JPD-212976","article-title":"Monoamine Oxidase-B inhibitors for the treatment of Parkinson's Disease: past, present, and future","volume":"12","author":"Tan","year":"2022","journal-title":"J. Parkinsons Dis."},{"issue":"4","key":"10.1016\/j.parkreldis.2026.108939_bib25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1468-1331.2008.02514.x","article-title":"The effect of onset age on the clinical features of Parkinson's disease","volume":"16","author":"Wickremaratchi","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"15","key":"10.1016\/j.parkreldis.2026.108939_bib26","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1212\/WNL.0000000000002461","article-title":"Age at onset and Parkinson disease phenotype","volume":"86","author":"Pagano","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2026.108939_bib27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1749-6632.2009.05118.x","article-title":"The progression of pathology in Parkinson's disease","volume":"1184","author":"Halliday","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.parkreldis.2026.108939_bib28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/jnnp.56.1.65","article-title":"Age influences magnitude but not duration of response to levodopa","volume":"56","author":"Durso","year":"1993","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.parkreldis.2026.108939_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261302","article-title":"Profiling the most elderly Parkinson'S disease patients: does age or disease duration matter?","volume":"16","author":"Virameteekul","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.parkreldis.2026.108939_bib30","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.parkreldis.2014.12.011","article-title":"Prognostic factors for early mortality in Parkinson's disease","volume":"21","author":"Oosterveld","year":"2015","journal-title":"Park. Relat. Disord."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802026007662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802026007662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:34:32Z","timestamp":1791358472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802026007662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"alternative-id":["S1353802026007662"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2026.108939","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of early adjunctive dopaminergic therapy and 5-year mortality in Parkinson's disease: A nationwide cohort study","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2026.108939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108939"}}